IDH-305

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameIDH-305
Drug Alias NameIDH-305
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmic
Therapy Area/IndicationsGliomaLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesUniversity of Texas Southwestern Medical Center
Active IndicationsNeoplasms
Inactive IndicationsGliomaLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A